![CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6078-2/MediaObjects/12885_2019_6078_Fig1_HTML.png)
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text
![Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study - Lung Cancer Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c729cd07-dc4f-4e03-8f40-db5ab2773e0a/gr1.jpg)
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study - Lung Cancer
![Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study - Igarashi - Annals of Gastroenterological Surgery ... Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study - Igarashi - Annals of Gastroenterological Surgery ...](https://onlinelibrary.wiley.com/cms/asset/ac9cf39b-8efa-4cdb-af75-c16da25bb286/ags312613-fig-0001-m.jpg)
Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study - Igarashi - Annals of Gastroenterological Surgery ...
![SUO 2018: Development of Serum MicroRNA as a Novel and Better Tumor Marker for Testicular Germ Cell Tumor than HCG and AFP SUO 2018: Development of Serum MicroRNA as a Novel and Better Tumor Marker for Testicular Germ Cell Tumor than HCG and AFP](https://www.urotoday.com/images/Screen_Shot_2018-11-30_at_12.24.11_PM.png)
SUO 2018: Development of Serum MicroRNA as a Novel and Better Tumor Marker for Testicular Germ Cell Tumor than HCG and AFP
![Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas | Anticancer Research Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/42/3/1509/F1.large.jpg)
Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas | Anticancer Research
![Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment | BMC Gastroenterology | Full Text Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment | BMC Gastroenterology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12876-021-01785-7/MediaObjects/12876_2021_1785_Fig6_HTML.png)